Myonexus
develops gene therapies for the treatment of limb girdle muscular dystrophies... Read moreMyonexus
develops gene therapies for the treatment of limb girdle muscular dystrophies... Read more
News
Mar 08, 2019
Muscular Dystrophy News
Myonexus: MYO-101 Enables Production of Missing Protein in Children with LGMD2E, Trial Shows
Feb 27, 2019
BioSpace
Myonexus: Myonexus Therapeutics Announces Accelerated Acquisition by Sarepta Therapeutics
Feb 27, 2019
Reuters
Myonexus: Sarepta to buy gene therapy developer Myonexus for $165 mln
Jan 04, 2019
Muscular Dystrophy News
Myonexus: Myonexus' MYO-102 Earns FDA's Orphan Drug Status for LGMD 2D
Jan 02, 2019
PharmiWeb
Myonexus: Myonexus Therapeutics Receives Orphan Drug Designation for MYO-102, an Investigational Gene Therapy for Alpha-sarcoglycanopathy (LGMD2D)
Nov 08, 2018
BioPortfolio
Myonexus: Myonexus Therapeutics Announces the Initiation of a Trial for the FirstEver Gene Therapy for Betasarcoglycanopathy Also Known as LimbGirdle Muscular Dystrophy Type 2E
Nov 07, 2018
Myonexus Youtube Channel
Myonexus posted a video "The Myonexus LGMD Gene Therapy Platform" on YOUTUBE
Nov 07, 2018
Myonexus Youtube Channel
Myonexus posted a video "Understanding MYO-101" on YOUTUBE
May 17, 2018
BioPortfolio
Myonexus: Myonexus Receives FDA Rare Pediatric Drug Designation for Investigational Treatment of Limb Girdle Muscular Dystrophy Type 2E
May 04, 2018
FierceBiotechIT
Myonexus: Sarepta adds muscular dystrophy gene therapies via Myonexus pact
Myonexus Competitors
1
2
3
4
5
6
7
8
9
10